Table 4 Adverse events observed under vinblastine + steroid treatment throughout the study

At least one adverse event, n (%)

16 (46%)

Non-neurological adverse events

14 (40%)

Neutropenia

6 (17%)

 grade 3/4

4/2

Herpes zoster

1 (3%)

Catheter-related septicemia (grade 4)

1 (3%)

Digestive disorders

4 (11%)

 grade 1

3

 grade 2^a

1

Alopecia (grade 1)

1 (3%)

Muscular pain (grade 1)

2 (6%)

Steroid related adverse events

2 (6%)

 weight gain (grade 3)

1

 weight gain and de novo diabetes (grade 3)

1

Neurological adverse events

9 (26%)

Peripheral sensitive neuropathy (grade 2)

9 (26%)

Peripheral motor neuropathy^b (grade 2)

1 (3%)